Phosphorylated tau is a modified form of the tau protein in which phosphate groups are added to specific serine, threonine, or tyrosine amino acid residues, altering its function and properties.
In healthy neurons, tau normally contains approximately 2-3 moles of phosphate per mole of protein and functions to stabilize microtubules and facilitate axonal transport.
Hyperphosphorylated tau, carrying 6-8 moles of phosphate per mole in Alzheimer’s disease, loses its ability to bind microtubules and instead self-aggregates into paired helical filaments that form neurofibrillary tangles.
This hyperphosphorylation occurs at more than 40 potential sites on the tau protein, with some sites only phosphorylated in disease states.
The phosphorylation state of tau is regulated by the balance between protein kinases (including proline-directed kinases, glycogen synthase kinase 3β, and cyclin-dependent kinase 5) and phosphatases (particularly PP2A).
Different phosphorylation sites serve distinct functions—for example, phosphorylation at Ser396 or Ser404 in the C-terminal domain drives tau mislocalization to dendritic spines, while phosphorylation in the proline-rich region leads to postsynaptic dysfunction.
Phosphorylated tau species measured in cerebrospinal fluid and plasma (such as p-tau181, p-tau217, and p-tau231) serve as biomarkers for Alzheimer’s disease, correlating strongly with amyloid pathology and helping predict disease progression.
These soluble phosphorylated forms are distinct from the insoluble aggregated tau detected by PET imaging.